


OncolIndx® TBx offers integrated genomic and transcriptomic profiling across solid tumors. Its unique design identifies key actionable insights for personalizing cancer treatment.



OncolIndx® TBx in practice

- Challenges of managing complex cancers are addressed through evidence-based treatment choice.
- NGS report enhanced with artificial intelligence and updated clinical studies help identify the most beneficial therapeutic options.
- An easy digital interface to interpret and understand complex cancer genomics.

Where is OncolIndx® TBx needed?

- Cancers progressing on standard-of-care treatment.
- Cancers where personalised treatment could enhance survival.
- Cancers showing resistance to conventional treatment.
- Cancers where combination of target drugs and/or immunotherapy could benefit.

Designed for oncologists managing complex, advanced and refractory cancer patients.

Clinical and Technical Validation of OncolIndx® Assay

Alteration	*PPV	*NPV	Accuracy	Specificity	Sensitivity
SNVs	100	100	100	100	100
Small INDELs	100	94.03	97.40	100	95.60
CNA	100	100	100	100	100
Fusions	100	96.43	98.48	100	97.44


Validation summary for RNA sequencing Based Fusion Detection Assay

Sensitivity	PPV	NPV	Specificity	Precision
78.6%	100%	82%	100%	≥95%
Accuracy				LOD (empirical)
≥95% Within validated input range				≥20ng RNA input with ≥60X coverage

*PPV: Positive Predictive Value; NPV: Negative Predictive Value

- Proprietary panel of 1,000+ genes
- Longitudinal monitoring markers
- PD-L1 through IHC (TBx)
- Traceability to ongoing clinical trials worldwide

OncolIndx® TBx



Key Actionable Genes Include:



Lung

EGFR, ALK, HRAS, NRAS, KRAS, BRAF, TERT, ROS1, MET, RET, NTRK1/2/3, ERBB2, PIK3CA



Breast

BRCA1, BRCA2, HER2, PIK3CA, MSH6, PMS2, NTRK1/2/3, MLH1, BRAF



Bladder

FGFR2/3, NTRK1/2/3



Colorectal

BRAF, KRAS, NRAS, HRAS, ERBB2, MLH1, MSH2, MSH6, PMS2, NTRK1/2/3



Gastrointestinal

ALK, HRAS, HER2, NRAS, KRAS, BRAF, TERT, ROS1, MET, RET, NTRK1/2/3



Melanoma

BRAF, KIT, ROS1, NTRK1/2/3



Prostate

BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, AR, NTRK1/2/3



Thyroid

ALK, HRAS, NRAS, KRAS, BRAF, TERT, RET, NTRK1/2/3



Ovary

BRCA1, BRCA2, HER2, PMS2, MLH1, MSH2, MSH6, NTRK1/2/3

Features of Oncolndx® TBx report

- In accordance to international guidelines.
- Clear, unambiguous and actionable genomic and transcriptomic findings.
- Based on highly reliable and internally curated databases.



Techincal Specification

Specimen	Tissue
Panel Size	3 MB
Sample Type	1 FFPE tissue block with 20-30 % tumor content (not more than 3-4 months old)*
Sample Collection	FFPE tissue block
Sample volume/quantity	1 FFPE block with 20-30% tumor content
DNA input amount	> 1ng
Sequencing platform	Illumina
Read Length	2 x 150bp
Mean Sequencing Depth	2000x
Sequencing Chemistry	Hybrid capture
Indications	Solid Tumor
Analysis and Reporting	iCare™- AI based analysis platform with active reporting options

Oncolndx® TBx is an integrated NGS test that provides clarity to make impactful clinical decisions.

1080 genes panel

Comprehensive gene panel of targetable/therapeutic significance

>99% on target coverage

High quality, reliable results for therapy selection

2000x mean depth

Ultra deep sequencing for sensitive, reliable detection



1Cell.AiTM
Ai-Powered Precision Oncology



MC-7348

Learn More at 1Cell.ai

Mail - info@1cell.ai | Tel - 1800 123 12355

1Cell.Ai © Copyright 2025. All rights reserved | Scan QR to know more



1CAi-13-01-012025